These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 24294538)

  • 21. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
    Ford D; Easton DF; Stratton M; Narod S; Goldgar D; Devilee P; Bishop DT; Weber B; Lenoir G; Chang-Claude J; Sobol H; Teare MD; Struewing J; Arason A; Scherneck S; Peto J; Rebbeck TR; Tonin P; Neuhausen S; Barkardottir R; Eyfjord J; Lynch H; Ponder BA; Gayther SA; Zelada-Hedman M
    Am J Hum Genet; 1998 Mar; 62(3):676-89. PubMed ID: 9497246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
    J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred.
    Vogl FD; Badzioch MD; Steele L; Neuhausen SL; Goldgar DE
    Fam Cancer; 2007; 6(1):63-71. PubMed ID: 17051349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts.
    Shin SJ; Dodd-Eaton EB; Peng G; Bojadzieva J; Chen J; Amos CI; Frone MN; Khincha PP; Mai PL; Savage SA; Ballinger ML; Thomas DM; Yuan Y; Strong LC; Wang W
    Cancer Res; 2020 Jan; 80(2):354-360. PubMed ID: 31719101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes.
    Schramm C; Charbonnier C; Zaréa A; Lacour M; Wallon D; ; Boland A; Deleuze JF; Olaso R; ; Alarcon F; Campion D; Nuel G; Nicolas G
    Genome Med; 2022 Jun; 14(1):69. PubMed ID: 35761418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selected Aspects of Molecular Diagnostics of Constitutional Alterations in BRCA1 and BRCA2 Genes Associated with Increased Risk of Breast Cancer in the Polish Population.
    Górski B
    Hered Cancer Clin Pract; 2006 Aug; 4(3):142-52. PubMed ID: 20223018
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating penetrance from family data using a retrospective likelihood when ascertainment depends on genotype and age of onset.
    Carayol J; Bonaïti-Pellié C
    Genet Epidemiol; 2004 Sep; 27(2):109-17. PubMed ID: 15305327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.
    Walsh T; Casadei S; Coats KH; Swisher E; Stray SM; Higgins J; Roach KC; Mandell J; Lee MK; Ciernikova S; Foretova L; Soucek P; King MC
    JAMA; 2006 Mar; 295(12):1379-88. PubMed ID: 16551709
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.
    Anglian Breast Cancer Study Group
    Br J Cancer; 2000 Nov; 83(10):1301-8. PubMed ID: 11044354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach.
    Fu R; Harris EL; Helfand M; Nelson HD
    Stat Med; 2007 Apr; 26(8):1775-87. PubMed ID: 17243094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical implementation of frailty models in Mendelian risk prediction.
    Huang T; Gorfine M; Hsu L; Parmigiani G; Braun D
    Genet Epidemiol; 2020 Sep; 44(6):564-578. PubMed ID: 32506746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A competing risks model with binary time varying covariates for estimation of breast cancer risks in
    Choi YH; Jung H; Buys S; Daly M; John EM; Hopper J; Andrulis I; Terry MB; Briollais L
    Stat Methods Med Res; 2021 Sep; 30(9):2165-2183. PubMed ID: 34232831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of association studies to define genetic modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers.
    Hughes DJ
    Fam Cancer; 2008; 7(3):233-44. PubMed ID: 18283561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history.
    Berry DA; Parmigiani G; Sanchez J; Schildkraut J; Winer E
    J Natl Cancer Inst; 1997 Feb; 89(3):227-38. PubMed ID: 9017003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age-dependent penetrance of different germline mutations in the BRCA1 gene.
    Al-Mulla F; Bland JM; Serratt D; Miller J; Chu C; Taylor GT
    J Clin Pathol; 2009 Apr; 62(4):350-6. PubMed ID: 19329713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hereditary breast cancer; Genetic penetrance and current status with BRCA.
    Mahdavi M; Nassiri M; Kooshyar MM; Vakili-Azghandi M; Avan A; Sandry R; Pillai S; Lam AK; Gopalan V
    J Cell Physiol; 2019 May; 234(5):5741-5750. PubMed ID: 30552672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast and ovarian cancer penetrance of
    Zhang L; Shin VY; Chai X; Zhang A; Chan TL; Ma ES; Rebbeck TR; Chen J; Kwong A
    Oncotarget; 2018 May; 9(38):25025-25033. PubMed ID: 29861850
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bayesian Semiparametric Estimation of Cancer-specific Age-at-onset Penetrance with Application to Li-Fraumeni Syndrome.
    Shin SJ; Yuan Y; Strong LC; Bojadzieva J; Wang W
    J Am Stat Assoc; 2019; 114(526):541-552. PubMed ID: 31485091
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.